Harvard Bioscience
Harvard Bioscience's revenue fell 8.1% to $86 million in fiscal 2025. Its operating margin was −56.1%, down from −6.6% a year earlier. Free cash flow was $5 million. The diluted share count rose 2.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Harvard Bioscience lost money in fiscal 2025: a net loss of $57 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 8 | 4 | 4 | 4 | 9 |
| Debt incl. finance leases | 48 | 47 | 37 | 37 | 36 |
| Net debt (negative means net cash) | 40 | 42 | 32 | 33 | 27 |
| Net debt to EBITDA | 4.2x | 65.9x | 3.6x | 42.6x | — |
| Debt to equity | 0.6x | 0.7x | 0.5x | 0.6x | 2.6x |
| Interest coverage | 1.3x | −3.0x | 0.5x | −1.9x | −13.5x |
| Current ratio | 2.4x | 2.2x | 1.9x | 0.8x | 2.2x |
| Quick ratio | 1.3x | 1.1x | 0.9x | 0.4x | 1.2x |
Cash flow
Projections
Project Harvard Bioscience's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $202,354 of Harvard Bioscience shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Stephen J DenelskyDirector | Bought | 10,000 | $4.87 | $48,700 | Form 4 |
| Mar 17, 2026 | William SniderDirector | Bought | 8,475 | $4.85 | $41,104 | Form 4 |
| Mar 16, 2026 | William SniderDirector | Bought | 12,525 | $4.99 | $62,500 | Form 4 |
| Mar 16, 2026 | John D DukeChief Executive Officer, Director | Bought | 5,000 | $5.01 | $25,050 | Form 4 |
| Mar 16, 2026 | Mark T FrostChief Financial Officer | Bought | 5,000 | $5.00 | $25,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 2 of 9 | 3 of 9 |
| Rule of 40 | 9.9% | −17.4% | −1.7% |
| Altman Z'' | −1.10 | −3.86 | −10.45 |
| Accruals ratio | −12.3% | −10.5% | −61.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 6 of 9 | 2 of 9 | 3 of 9 |
Compare
Put Harvard Bioscience side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Harvard Bioscience | FY25 | −8.1% | −56.1% | 6.3% | −56.0% | — | 3 | |
| Standard Biotools | FY25 | −6.2% | −129.2% | −96.8% | −41.9% | — | 4 | Compare |
| Codexis | FY25 | 18.6% | −59.3% | −33.9% | −189.5% | — | 4 | Compare |
| Personalis | FY25 | −17.7% | −126.4% | −114.1% | — | — | — | Compare |
| Quanterix | FY25 | 1.1% | −90.4% | −57.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 104 | 77 | 121 | 116 | 102 | 119 | 113 | 112 | 94 | 86 |
| Revenue growth | −3.8% | −25.9% | 56.0% | −3.8% | −12.1% | 16.5% | −4.7% | −1.0% | −16.1% | −8.1% |
| Gross profit | 48 | 39 | 63 | 64 | 58 | 68 | 61 | 66 | 55 | 50 |
| Research and development | 5 | 6 | 11 | 11 | 9 | 11 | 12 | 12 | 10 | 9 |
| Operating income | −3 | −1 | 1 | 0 | 0 | 2 | −7 | 2 | −6 | −49 |
| Net income | −4 | −1 | −3 | −5 | −8 | −0 | −10 | −3 | −12 | −57 |
| Diluted EPS (US$) | −0.13 | −0.02 | −0.08 | −0.12 | −0.20 | −0.01 | −0.23 | −0.08 | −0.28 | −1.28 |
| Diluted shares (millions) | 34 | 35 | 36 | 38 | 39 | 40 | 41 | 42 | 44 | 44 |
| Cash flow | ||||||||||
| Cash from operations | 5 | 1 | 3 | 8 | 9 | 1 | 1 | 14 | 1 | 7 |
| Capital expenditure | — | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 1 |
| Free cash flow | — | 0 | 2 | 7 | 8 | 0 | −0 | 12 | −1 | 5 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 68 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 4 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 6 | 5 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 9 |
| Debt incl. finance leases | 14 | 12 | 61 | 54 | 48 | 48 | 47 | 37 | 37 | 36 |
| Total assets | 108 | 109 | 169 | 165 | 156 | 162 | 145 | 137 | 127 | 80 |
| Total liabilities | 36 | 28 | 86 | 83 | 80 | 79 | 73 | 64 | 63 | 66 |
| Shareholders' equity | 72 | 81 | 83 | 82 | 77 | 83 | 72 | 73 | 63 | 14 |
| Margins and ratios | ||||||||||
| Gross margin | 46.3% | 50.6% | 52.3% | 55.4% | 56.9% | 56.9% | 53.7% | 58.9% | 58.2% | 57.7% |
| Operating margin | −2.9% | −0.8% | 0.8% | 0.3% | 0.2% | 1.7% | −6.1% | 1.7% | −6.6% | −56.1% |
| Net margin | −4.1% | −1.1% | −2.4% | −4.0% | −7.7% | −0.2% | −8.4% | −3.0% | −13.2% | −65.5% |
| Free cash flow margin | — | 0.2% | 1.6% | 5.9% | 8.0% | 0.1% | −0.4% | 10.9% | −1.3% | 6.3% |
| Rule of 40 (growth + FCF margin) | — | −25.7% | 57.6% | 2.1% | −4.1% | 16.5% | −5.1% | 9.9% | −17.4% | −1.7% |
| Return on capital | −2.8% | −0.6% | 0.7% | 0.2% | 0.1% | 1.4% | −4.6% | 1.4% | −4.9% | −56.0% |
| Return on equity | −5.8% | −1.1% | −3.6% | −5.7% | −9.9% | −0.4% | −12.2% | −4.7% | −18.2% | −147.1% |
| Return on assets | −3.8% | −0.8% | −2.1% | −2.8% | −4.9% | −0.2% | −6.2% | −2.4% | −9.4% | −54.9% |
| Net debt to EBITDA | 6.6x | 3.0x | 6.0x | 5.6x | 5.0x | 4.2x | 65.9x | 3.6x | 42.6x | — |